Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction

Molecular and Cellular Biochemistry

Volumn 321, Issue 1-2, 2009, Pages 9-22

  Palaniyappan, Arivazhagan ^a   Uwiera, Richard R E ^a   Idikio, Halliday ^a   Jugdutt, Bodh I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin II type 1 receptor blocker; Cytokines; Extracellular matrix; Myeloperoxidase; Reperfused myocardial infarction; Vasopeptidase inhibitor; Ventricular remodeling

Indexed keywords

CANDESARTAN; COLLAGEN; CYTOKINE; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; MYELOPEROXIDASE; OMAPATRILAT; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; EXTRACELLULAR MATRIX; HEALING; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART VENTRICLE REMODELING; NONHUMAN; PRESSOR RESPONSE; RAT; SYSTOLE; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; CARDIOVASCULAR AGENTS; CYTOKINES; EXTRACELLULAR MATRIX; HUMANS; ISOENZYMES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDIAL REPERFUSION; MYOCARDIUM; NITRIC OXIDE SYNTHASE; PEROXIDASE; PROTEASE INHIBITORS; PYRIDINES; RANDOM ALLOCATION; RATS; TETRAZOLES; THIAZEPINES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-3; VENTRICULAR REMODELING;

RATTUS;

EID: 58249137337     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-008-9905-3     Document Type: Article

References (36)

1. Jugdutt BI (2003) Ventricular remodeling post-infarction and the extracellular collagen matrix. When is enough enough? Circulation 108:1395-1403. doi: 10.1161/01.CIR.0000085658.98621.49
2. Jugdutt BI (2003) Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord 3:1-30. doi: 10.2174/1568006033337276
3. Sawicki G, Menon V, Jugdutt BI (2004) Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT 1 receptor blockade. J Card Fail 10:442-449. doi: 10.1016/ j.cardfail.2004.01.012
4. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al (2002) Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilation and long-term prognostic implications. Circulation 106:2351-2357. doi: 10.1161/ 01.CIR.0000036014.90197.FA
5. Jugdutt BI (2006) Matrix metalloproteinases as markers of adverse remodeling after myocardial infarction. J Card Fail 12:73-76. doi: 10.1016/j.cardfail.2005.10.001
6. Jugdutt BI (2002) Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev 7:391-405. doi: 10.1023/ A:1020718619155
7. Sawicki G, Jugdutt BI (2007) Valsartan reverses post-translational modifications of the δ-subunit of ATP synthase during in vivo canine reperfused myocardial infarction. Proteomics 42:2100-2110. doi: 10.1002/pmic.200601022
8. Vasilyev N, Williams T, Brennan ML et al (2005) Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 112:2812-2820. doi: 10.1161/CIRCULATIONAHA.105.542340
9. Yasmin W, Strynadka KD, Schulz R (1997) Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 33:422-432. doi: 10.1016/S0008-6363(96)00254-4
10. Mungrue IN, Husain M, Stewart DJ (2002) The role of NOS in heart failure: Lessons from the murine genetic models. Heart Fail Rev 7:407-422. doi: 10.1023/A:1020762401408
11. Jugdutt BI (2006) Valsartan in the treatment of heart attack survivors. J Vasc Health Risk Manag 2:125-138. doi: 10.2147/vhrm.2006.2.2.125
12. Granger CB, McMurray JJV, Yusuf S, CHARM Investigators Committees et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-alternative trial. Lancet 362:772-776. doi: 10.1016/S0140-6736(03)14284-5
13. Jugdutt BI, Idikio H, Uwiera RER (2007) Angiotensin receptor blockade and angiotensin-converting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction. Mol Cell Biochem 303:27-38. doi: 10.1007/s11010-007-9452-3
14. Burnett JC Jr (1999) Vasopeptidase inhibition: A new concept in blood pressure management. J Hypertens 17:S37-S43
15. Burrell LM, Farina NK, Balding LC, Johnston CI (2000) Beneficial renal and cardiac effects of vasopeptidase inhibition with S31402 in heart failure. Hypertension 36:1105-1111
16. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T (1998) Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: Role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol 31:116-125. doi: 10.1097/ 00005344-199801000-00017
17. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM (1999) Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 34:782-790. doi: 10.1097/ 00005344-199912000-00003
18. Xu J, Carretero OA, Liu YH et al (2004) Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail 10:83-89
19. Packer M, Califf RM, Konstam MA et al (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 106:920-926. doi: 10.1161/ 01.CIR.0000029801.86489.50
20. Rouleau JL, Pfeffer MA, Stewart DJ et al (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356:615-620. doi: 10.1016/S0140-6736(00)02602-7
21. Lapointe N, Blais C Jr, Adam A et al (2002) Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol 39:1692-1698. doi: 10.1016/S0735-1097(02)01837-5
22. Solomon SD, Skali H, Bourgoun M et al (2005) Effect of angiotensin-converting-enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE) echocardiographic study. Am Heart J 150:257-262. doi: 10.1016/ j.ahj.2004.09.056
23. 1 receptor blockade in reperfused myocardial infarction in the rat. Mol Cell Biochem 262:203-214. doi: 10.1023/ B:MCBI.0000038236.59905.8b
24. Jugdutt BI, Menon V (2004) Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction. J Card Fail 10:74-82. doi: 10.1016/S1071-9164(03)00584-0
25. Reffelmann T, Hale SL, Dow JS, Kloner RA (2003) No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation 108:2911-2917. doi: 10.1161/ 01.CIR.0000101917.80668.E1
26. Matsumura K, Jeremy RW, Schaper J, Becker LC (1998) Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 97:795-804
27. Jugdutt BI, Joljart MJ, Khan MI (1996) Rate of collagen deposition during healing after myocardial infarction in the rat and dog models: mechanistic insights into ventricular remodeling. Circulation 94:94-101
28. Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE (1995) Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Circulation 92:926-934
29. Watson EL, Sheth M, Denyer RF, Dostal DE (2004) Baseline echocardiographic values for adult male rats. J Am Soc Echocardiogr 17:161-167. doi: 10.1016/j.echo.2003.10.010
30. Goldman S, Shalev E (2006) Difference in progesterone-receptor isoforms ratio between early and late first-trimester human trophoblast is associated with differential cell invasion and matrix metalloproteinase 2 expression. Biol Reprod 74:13-22. doi: 10.1095/biolreprod.105.044925
31. Mullane KM, Kraemer MR, Smith B (1985) Myeloperoxidase activity as a quantitative of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 14:156-167. doi: 10.1016/0160-5402(85)90029-4
32. Frangiogiannis NG, Smith CW, Entman ML (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53:31-47. doi: 10.1016/ S0008-6363(01)00434-5
33. Wang D, Yang XP, Liu YH, Carretero OA, LaPointe MC (1999) Reduction of myocardial infarct size by inhibition of inducible nitric oxide synthase. Am J Hypertens 12(2 Pt 1):174-182. doi: 10.1016/ S0895-7061(98)00235-0
34. Zhang X, Recchia FA, Bernstein R, Xu X, Nasjletti A, Hintze TH (1999) Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment of heart failure. J Pharmacol Exp Ther 288:742-751
35. Wang CH, Leung N, Lapointe N et al (2003) Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in zucker fatty rats. Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Circulation 107:1923-1929. doi: 10.1161/01.CIR.0000062646.09566.CC
36. Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo CA Jr (2008) Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma J 100:327-332